NO20083793L - Antistoffer mot amyloid-beta peptid - Google Patents

Antistoffer mot amyloid-beta peptid

Info

Publication number
NO20083793L
NO20083793L NO20083793A NO20083793A NO20083793L NO 20083793 L NO20083793 L NO 20083793L NO 20083793 A NO20083793 A NO 20083793A NO 20083793 A NO20083793 A NO 20083793A NO 20083793 L NO20083793 L NO 20083793L
Authority
NO
Norway
Prior art keywords
antibodies
amyloid
beta peptide
methods
elevated
Prior art date
Application number
NO20083793A
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Volker Germaschewski
Stephen Anthony Burbidge
Susannah K Ford
Umesh Kumar
Karen Louise Philpott
Peter Ernest Soden
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20083793L publication Critical patent/NO20083793L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Sammendrag Antistoffer som binder human ß-amyloid protein, fremgangsmåter for behandling av sykdommer eller lidelser karakterisert ved forhøyet ß-amyloidnivåer eller ß-amyloidavsetninger med nevnte antistoffer, farmasøytiske preparater omfattende nevnte antistoffer og fremgangsmåter forfremstilling. 1
NO20083793A 2006-03-30 2008-09-03 Antistoffer mot amyloid-beta peptid NO20083793L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78758806P 2006-03-30 2006-03-30
PCT/EP2007/052928 WO2007113172A2 (en) 2006-03-30 2007-03-27 Antibodies against amyloid-beta peptide

Publications (1)

Publication Number Publication Date
NO20083793L true NO20083793L (no) 2008-10-13

Family

ID=38284050

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20083793A NO20083793L (no) 2006-03-30 2008-09-03 Antistoffer mot amyloid-beta peptid

Country Status (33)

Country Link
US (3) US8227576B2 (no)
EP (2) EP1996621B1 (no)
JP (1) JP5103466B2 (no)
KR (2) KR101263294B1 (no)
CN (2) CN101415729B (no)
AR (1) AR060332A1 (no)
AT (1) ATE451392T1 (no)
AU (1) AU2007233831B2 (no)
BR (1) BRPI0709246A2 (no)
CA (1) CA2647808C (no)
CR (1) CR10347A (no)
CY (1) CY1109877T1 (no)
DE (1) DE602007003703D1 (no)
DK (2) DK2177536T3 (no)
EA (1) EA015654B9 (no)
ES (2) ES2484967T3 (no)
HK (2) HK1138015A1 (no)
HR (2) HRP20100115T1 (no)
IL (1) IL193695A (no)
JO (1) JO2576B1 (no)
MA (1) MA30337B1 (no)
MX (1) MX2008012483A (no)
MY (1) MY149630A (no)
NO (1) NO20083793L (no)
NZ (1) NZ571038A (no)
PE (1) PE20080181A1 (no)
PL (2) PL2177536T3 (no)
PT (2) PT2177536E (no)
SI (2) SI2177536T1 (no)
TW (1) TWI385179B (no)
UA (1) UA94734C2 (no)
WO (1) WO2007113172A2 (no)
ZA (1) ZA200807911B (no)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
CN1747747B (zh) 2003-01-06 2012-09-05 安吉奥开米公司 作为穿过血脑屏障的载体的抑酶肽及类似物
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP2008523815A (ja) 2004-12-15 2008-07-10 エラン ファーマ インターナショナル リミテッド 認知の改善における使用のためのヒト化アミロイドβ抗体
AU2006208226A1 (en) 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
PL2046833T3 (pl) 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US7931899B2 (en) 2007-05-14 2011-04-26 Medtronic, Inc Humanized anti-amyloid beta antibodies
US8323654B2 (en) 2007-05-14 2012-12-04 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
JP5889529B2 (ja) * 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
BRPI0815576A2 (pt) * 2007-08-20 2015-02-18 Glaxo Group Ltd Método para produzir uma linha celular que produz uma proteína terapêutica, segunda linha celular transformada com uma segunda seqüência de polinucleotídeos, vetor, cassete de expressão amplificado, linha celular ou sua progênie, e, anticorpo.
GB0718737D0 (en) * 2007-09-25 2007-11-07 Glaxo Group Ltd Antibodies
UA101167C2 (ru) * 2007-10-05 2013-03-11 Дженентек, Инк. Фармацевтическая композиция, предназначенная для лечения глазной болезни
SG10201505369QA (en) 2007-10-05 2015-08-28 Genentech Inc Use of anti-amyloid beta antibody in ocular diseases
MX2010003622A (es) * 2007-10-12 2010-04-14 Hoffmann La Roche Expresion proteinica a partir de acidos nucleicos multiples.
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2586797A3 (en) * 2007-11-27 2013-07-24 Medtronic, Inc. Humanized anti-amyloid beta antibodies
TWI388334B (zh) * 2007-12-11 2013-03-11 Glaxo Group Ltd 抗原結合蛋白質
EP2235058A2 (en) * 2007-12-21 2010-10-06 Amgen, Inc Anti-amyloid antibodies and uses thereof
AR071634A1 (es) 2008-05-06 2010-06-30 Glaxo Group Ltd Nanoparticulas para encapsulacion de agentes biologicamente activos
JP2012505637A (ja) 2008-10-15 2012-03-08 アンジオケム，インコーポレーテッド Ｇｌｐ−１アゴニストのコンジュゲート及びその使用
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
CN102307904A (zh) 2008-12-05 2012-01-04 安吉奥开米公司 神经降压素或神经降压素类似物的缀合物及其用途
AU2010239069B2 (en) 2009-04-20 2015-05-14 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog
CA2766537A1 (en) * 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
NZ598685A (en) 2009-09-11 2013-05-31 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
EP2308897A1 (en) * 2009-10-09 2011-04-13 Pierre Fabre Medicament Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer
AU2011222980B2 (en) 2010-03-03 2016-08-11 Ablynx N.V. Biparatopic Abeta binding polypeptides
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
WO2011149461A1 (en) * 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
KR101713365B1 (ko) 2010-07-30 2017-03-08 에이씨 이뮨 에스.에이. 안전하고 기능적인 인간화 항 베타-아밀로이드 항체
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
SI2646470T1 (sl) * 2010-11-30 2017-05-31 F. Hoffmann-La Roche Ag Protitelesa proti receptorjem antitransferina in njihova uporaba za prenos terapevtskega enoverižnega variabilnega fragmenta (scfv) prek krvno-možganske pregrade
WO2012106363A2 (en) 2011-01-31 2012-08-09 Intellect Neurosciences Inc. Treatment of tauopathies
UA118950C2 (uk) 2011-04-22 2019-04-10 Аптево Рісьорч Енд Девелопмент Ллс Поліпептид, який зв'язує специфічний мембранний антиген простати та комплекс т-клітинного рецептора
GB201113570D0 (en) * 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
SG11201407669QA (en) 2012-05-21 2014-12-30 Genentech Inc Methods for improving safety of blood-brain barrier transport
RU2509155C1 (ru) * 2012-10-25 2014-03-10 Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии
JP2016529482A (ja) 2013-06-19 2016-09-23 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ 新規アッセイ
CN104558172A (zh) * 2015-01-04 2015-04-29 东南大学 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用
JP6823055B2 (ja) 2015-06-15 2021-01-27 アンジオケム インコーポレーテッド 軟髄膜癌腫症の治療方法
AU2016326449A1 (en) 2015-09-21 2018-03-22 Aptevo Research And Development Llc CD3 binding polypeptides
WO2017072090A1 (en) * 2015-10-27 2017-05-04 Glaxosmithkline Intellectual Property Development Limited Combination therapy
MX2019015914A (es) 2017-06-29 2020-08-06 Univ Columbia Anticuerpos quiméricos para el tratamiento de enfermedades por deposición de amiloide.
US11382974B2 (en) 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa
US12018069B2 (en) 2018-06-28 2024-06-25 The Trustees Of Columbia University In The City Of New York Methods and compositions for imaging amyloid deposits
CN111094340B (zh) * 2018-07-17 2022-11-22 江苏恒瑞医药股份有限公司 抗Abeta抗体、其抗原结合片段及应用
CA3135170A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
BR112023001061A2 (pt) 2020-07-23 2023-04-04 Othair Prothena Ltd Anticorpos antiabeta
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
CN114591917B (zh) * 2022-05-07 2022-09-02 北京第一生物化学药业有限公司 产生结合β-淀粉样蛋白的抗体的杂交瘤细胞及其用途
CN114591918B (zh) * 2022-05-07 2022-07-26 北京第一生物化学药业有限公司 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途
KR102530956B1 (ko) * 2022-09-08 2023-05-11 주식회사 알츠코리아 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869262A (en) * 1992-01-27 1999-02-09 Icos Corporation Method for monitoring an inflammatory disease state by detecting circulating ICAM-R
EP2305709A1 (en) * 1997-04-09 2011-04-06 Intellect Neurosciences, Inc. Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods for use thereof
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US6428950B1 (en) * 1998-11-25 2002-08-06 Scios Inc. Assay to identify compounds that alter apolipoprotein E expression
KR100767146B1 (ko) * 2000-02-24 2007-10-15 워싱톤 유니버시티 Ａβ 펩티드를 격리시키는 인간화 항체
ATE398177T1 (de) * 2000-11-03 2008-07-15 David Gladstone Inst Verfahren zur behandlung von erkrankungen im zusammenhang mit apoe
WO2004029629A1 (en) * 2002-09-27 2004-04-08 Janssen Pharmaceutica N.V. N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
ITTO20020867A1 (it) * 2002-10-08 2004-04-09 Pro Cord Spa Schienale di sedia.
BR0315157A (pt) * 2002-10-09 2005-08-09 Rinat Neuroscience Corp Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste

Also Published As

Publication number Publication date
KR20120093400A (ko) 2012-08-22
EP2177536A1 (en) 2010-04-21
IL193695A0 (en) 2011-08-01
MY149630A (en) 2013-09-13
CN101415729A (zh) 2009-04-22
ATE451392T1 (de) 2009-12-15
DE602007003703D1 (de) 2010-01-21
WO2007113172A2 (en) 2007-10-11
PL2177536T3 (pl) 2014-11-28
HRP20100115T1 (hr) 2010-04-30
US8227576B2 (en) 2012-07-24
US9193784B2 (en) 2015-11-24
WO2007113172A3 (en) 2007-11-29
ES2338179T3 (es) 2010-05-04
JO2576B1 (en) 2011-02-27
ZA200807911B (en) 2009-11-25
EP1996621A2 (en) 2008-12-03
TWI385179B (zh) 2013-02-11
MA30337B1 (fr) 2009-04-01
DK2177536T3 (da) 2014-07-14
US20160024197A1 (en) 2016-01-28
EP1996621B1 (en) 2009-12-09
DK1996621T3 (da) 2010-04-19
CR10347A (es) 2008-10-29
KR20080113273A (ko) 2008-12-29
NZ571038A (en) 2011-03-31
CN103539857A (zh) 2014-01-29
CN101415729B (zh) 2013-09-04
IL193695A (en) 2012-05-31
HRP20140618T1 (hr) 2014-08-15
JP2009531380A (ja) 2009-09-03
MX2008012483A (es) 2008-10-10
JP5103466B2 (ja) 2012-12-19
HK1138015A1 (en) 2010-08-13
EP2177536B1 (en) 2014-06-04
UA94734C2 (ru) 2011-06-10
US20110142824A1 (en) 2011-06-16
SI2177536T1 (sl) 2014-09-30
TW200815466A (en) 2008-04-01
HK1122311A1 (en) 2009-05-15
CA2647808C (en) 2015-11-17
EA015654B1 (ru) 2011-10-31
US20140050719A1 (en) 2014-02-20
AR060332A1 (es) 2008-06-11
PT1996621E (pt) 2010-03-08
EA015654B9 (ru) 2012-01-30
AU2007233831B2 (en) 2013-02-14
PE20080181A1 (es) 2008-03-16
BRPI0709246A2 (pt) 2011-07-12
CY1109877T1 (el) 2014-09-10
CA2647808A1 (en) 2007-10-11
SI1996621T1 (sl) 2010-04-30
EA200801842A1 (ru) 2009-02-27
PT2177536E (pt) 2014-08-22
ES2484967T3 (es) 2014-08-12
KR101263294B1 (ko) 2013-06-04
AU2007233831A1 (en) 2007-10-11
PL1996621T3 (pl) 2010-05-31

Similar Documents

Publication Publication Date Title
NO20083793L (no) Antistoffer mot amyloid-beta peptid
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
UA109633C2 (uk) Антитіло людини проти тканинного фактора
IN2014CN03936A (no)
GEP20115324B (en) Tweak binding antibodies
EA200970262A1 (ru) Композиции и способы, относящиеся к антителам к глюкагоновым рецепторам
ECSP12012272A (es) Proteínas que se unen al tnf-?
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
NO20091387L (no) Antistoffer mot benmorfogene proteiner og reseptorer derav, fremgangsmater for deres anvendelse
EA201100694A1 (ru) Антитело к cd38 человека и его применение
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EP2650308A3 (en) Use of anti-amyloid beta antibody in ocular diseases
BRPI0513798A (pt) anticorpos anti-cd154
EA201301107A1 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
EA201170357A1 (ru) Инженерные антитела к il-13: композиции, способы и применение
EP2586795A3 (en) Use of anti-amyloid beta antibody in ocular diseases
EA201290671A1 (ru) Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р
WO2008112840A3 (en) Novel composition and methods for the treatment of immune related diseases
EA202190387A1 (ru) Антитело к cd38 человека и его применение
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

FC2A Withdrawal, rejection or dismissal of laid open patent application